The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.
 
Aung M. Tun
No Relationships to Disclose
 
Seth Maliske
No Relationships to Disclose
 
Yucai Wang
Consulting or Advisory Role - Loxo (Inst)
Research Funding - Genentech (Inst); Incyte (Inst); InnoCare (Inst); Novartis (Inst)
 
Matthew J. Maurer
No Relationships to Disclose
 
Ivana N. M. Micallef
No Relationships to Disclose
 
David James Inwards
Research Funding - Acerta Pharma (Inst)
 
Luis F. Porrata
No Relationships to Disclose
 
Allison Claire Rosenthal
No Relationships to Disclose
 
Mohamed Kharfan-Dabaja
Consulting or Advisory Role - Daiichi Sankyo
 
Jacob Orme
No Relationships to Disclose
 
Brian K. Link
Consulting or Advisory Role - Abbvie; Genentech/Roche; MEI Pharma
Research Funding - Genentech/Abbvie (Inst); Pharmacyclics/Janssen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
James Robert Cerhan
Consulting or Advisory Role - Janssen; Janssen
Research Funding - Celgene (Inst); Genentech (Inst); NanoString Technologies (Inst)
 
Carrie A. Thompson
No Relationships to Disclose
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
 
Thomas E. Witzig
Consulting or Advisory Role - Abbvie/Genentech (Inst); ADC Therapeutics; Celgene (Inst); Cellectar; Epizyme; Incyte (Inst); Karyopharm Therapeutics; MorphoSys (Inst); Portola Pharmaceuticals; Seagen (Inst); Tessa Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Debiopharm Group; Genentech (Inst); Kite/Gilead; MorphoSys (Inst); Selvita
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Umar Farooq
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Patrick B. Johnston
No Relationships to Disclose